Advertisement

Genkyotex Raises CHF25 Million in Series C Round Extension

03:00 EDT 9 Jul 2012 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Genkyotex, the leading developer of NOX inhibitors to treat oxygen-radical mediated diseases, announced today the closing of a CHF25 million (USD26 million) extension to its Series C financing. Investors in the Series C round, i...

Other Sources for this Article

Dr. Ursula Ney
CEO, Genkyotex
Tel: +41 22 880 1025
Mo: +44 7900 898 708
Email: ursula.ney@genkyotex.com
or
Mike Sinclair
Halsin Partners
Tel: +44 20 7318 2955
Mo: +44 7968 022075
Email: msinclair@halsin.com

NEXT ARTICLE

More From BioPortfolio on "Genkyotex Raises CHF25 Million in Series C Round Extension"

Search BioPortfolio: